These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 31475898)

  • 1. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 4. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
    Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
    Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
    Nastasă C; Tamaian R; Oniga O; Tiperciuc B
    Medicina (Kaunas); 2019 Mar; 55(4):. PubMed ID: 30935124
    [No Abstract]   [Full Text] [Related]  

  • 6. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
    He H; Xu C; Cheng Z; Qian X; Zheng L
    Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.
    Shao YT; Ma L; Zhang TH; Xu TR; Ye YC; Liu Y
    Curr Top Med Chem; 2019; 19(23):2143-2157. PubMed ID: 31456522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    Korzeniecki C; Priefer R
    Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Lethal Vulnerabilities in
    Aguirre AJ; Hahn WC
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.
    Perurena N; Cichowski K
    Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting KRAS in gynecological malignancies.
    Peng Y; Yang Q
    FASEB J; 2024 Oct; 38(19):e70089. PubMed ID: 39377766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discoveries in the redox regulation of KRAS.
    Kramer-Drauberg M; Ambrogio C
    Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.